UA113094C2 - Спосіб одержання аутологічного фібринового гелю для стимуляції регенерації кісткових і м'яких тканин і зниження інтенсивності запальних процесів - Google Patents
Спосіб одержання аутологічного фібринового гелю для стимуляції регенерації кісткових і м'яких тканин і зниження інтенсивності запальних процесів Download PDFInfo
- Publication number
- UA113094C2 UA113094C2 UAA201501207A UAA201501207A UA113094C2 UA 113094 C2 UA113094 C2 UA 113094C2 UA A201501207 A UAA201501207 A UA A201501207A UA A201501207 A UAA201501207 A UA A201501207A UA 113094 C2 UA113094 C2 UA 113094C2
- Authority
- UA
- Ukraine
- Prior art keywords
- fibrin gel
- enzyme
- obtaining
- blood plasma
- bone
- Prior art date
Links
- 108010073385 Fibrin Proteins 0.000 title claims abstract description 53
- 102000009123 Fibrin Human genes 0.000 title claims abstract description 53
- 229950003499 fibrin Drugs 0.000 title claims abstract description 53
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims description 15
- 230000004054 inflammatory process Effects 0.000 title abstract description 12
- 210000004872 soft tissue Anatomy 0.000 title abstract description 8
- 210000000988 bone and bone Anatomy 0.000 title abstract description 7
- 206010061218 Inflammation Diseases 0.000 title description 4
- 230000009467 reduction Effects 0.000 title description 3
- 230000000638 stimulation Effects 0.000 title description 3
- 230000017423 tissue regeneration Effects 0.000 title description 2
- 108010077727 ecamulin Proteins 0.000 claims abstract description 25
- 210000002381 plasma Anatomy 0.000 claims abstract description 23
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 3
- 230000003993 interaction Effects 0.000 claims abstract description 3
- 241001465754 Metazoa Species 0.000 claims description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 abstract description 7
- 230000000399 orthopedic effect Effects 0.000 abstract description 5
- 239000012190 activator Substances 0.000 abstract description 4
- 230000008929 regeneration Effects 0.000 abstract description 4
- 238000011069 regeneration method Methods 0.000 abstract description 4
- 108010094028 Prothrombin Proteins 0.000 abstract description 3
- 102100027378 Prothrombin Human genes 0.000 abstract description 3
- 229940039716 prothrombin Drugs 0.000 abstract description 3
- 239000002435 venom Substances 0.000 abstract description 3
- 210000001048 venom Anatomy 0.000 abstract description 3
- 231100000611 venom Toxicity 0.000 abstract description 3
- 241000270295 Serpentes Species 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 208000010392 Bone Fractures Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 230000000622 irritating effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 101001038021 Lonomia obliqua Lopap Proteins 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000002747 omentum Anatomy 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000243820 Polychaeta Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000013210 hematogenous Diseases 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- -1 2-octyl Chemical group 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000535 fibrinogen concentrate Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000007468 re-laparotomy Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA201501207A UA113094C2 (xx) | 2015-02-13 | 2015-02-13 | Спосіб одержання аутологічного фібринового гелю для стимуляції регенерації кісткових і м'яких тканин і зниження інтенсивності запальних процесів |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA201501207A UA113094C2 (xx) | 2015-02-13 | 2015-02-13 | Спосіб одержання аутологічного фібринового гелю для стимуляції регенерації кісткових і м'яких тканин і зниження інтенсивності запальних процесів |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA113094C2 true UA113094C2 (xx) | 2016-12-12 |
Family
ID=58044257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201501207A UA113094C2 (xx) | 2015-02-13 | 2015-02-13 | Спосіб одержання аутологічного фібринового гелю для стимуляції регенерації кісткових і м'яких тканин і зниження інтенсивності запальних процесів |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA113094C2 (xx) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021194461A1 (en) * | 2020-06-22 | 2021-09-30 | Palladin Instytute Of Biochemistry Of The National Academy Of Sciences Of Ukraine | The method of production of a haemostatic agent and a haemostatic agent for major bleeding control |
-
2015
- 2015-02-13 UA UAA201501207A patent/UA113094C2/uk unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021194461A1 (en) * | 2020-06-22 | 2021-09-30 | Palladin Instytute Of Biochemistry Of The National Academy Of Sciences Of Ukraine | The method of production of a haemostatic agent and a haemostatic agent for major bleeding control |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thorn et al. | Autologous fibrin glue with growth factors in reconstructive maxillofacial surgery | |
| JP4666764B2 (ja) | 血漿から安定で、長期型のトロンビンを調製するための装置および方法、並びにこれにより形成されたトロンビン | |
| DE69433939T2 (de) | Hämostatisches pflaster | |
| JP2018164757A (ja) | 単独でまたはヒアルロン酸と組み合わせて、多血小板血漿（ｐｒｐ）または骨髄遠心分離液（ｃｅｎｔｒａｔｅ）（ｂｍｃ）を調製するための新しい規格化および医療デバイス | |
| US20040197319A1 (en) | Wound healing composition derived from low platelet concentration plasma | |
| Fattahi et al. | Clinical applications of fibrin sealants | |
| DK165169B (da) | Anvendelse af stoffer fra blodplader til fremstilling af topiske saarhelingsmidler | |
| KR20050044725A (ko) | 저장-안정성 피브린 밀봉제 | |
| WO2017117996A1 (zh) | 一种外科止血生物制品及其使用方法 | |
| JPH02129224A (ja) | フィブリンの製造法 | |
| JP2016514716A (ja) | 組織の再生および創傷の治療のための植え込み型製剤、それらの製剤化方法、および該植え込み型製剤を用いる患者の治療方法 | |
| Burnouf et al. | Blood‐derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue | |
| Silberstein et al. | An autologous fibrinogen‐based adhesive for use in otologic surgery | |
| CA2787883C (en) | Method for improved fibrin sealing | |
| KR102260452B1 (ko) | 흡수성 체내용 지혈조성물의 제조방법 및 그에 따라 제조된 지혈조성물 | |
| US11744917B2 (en) | Tissular formulation or adhesive obtained from a blood composition containing platelets, and method for the preparation of said formulation | |
| US20080213229A1 (en) | Fibrin Contained Semi-Solid Osteoblast Composition for Curing Bone Fracture and Method for Producing the Same | |
| UA113094C2 (xx) | Спосіб одержання аутологічного фібринового гелю для стимуляції регенерації кісткових і м'яких тканин і зниження інтенсивності запальних процесів | |
| EP1528930A1 (de) | Thrombingenerierfähige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel | |
| Floyd et al. | Hemostasis and safety of a novel fibrin dressing versus standard gauze in bleeding cancellous bone in a caprine spine surgery model | |
| Goczyńska et al. | Fibrin glues—the current state of knowledge | |
| Burnouf | Blood-derived, tissue engineering biomaterials | |
| RU2790831C2 (ru) | Способ получения гемостатического состава | |
| RU2789967C1 (ru) | Способ клеевой фиксации септальных лоскутов слизистой оболочки в хоане у пациентов при хоанопластике | |
| Mustafa et al. | Application of platelet-rich plasma (PRP) in corneal lesions-a review. |